Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM).

Author:

Daud Adil1,Weber Jeffrey S.2,Sosman Jeffrey Alan3,Kim Kevin4,Gonzalez Rene5,Hamid Omid6,Infante Jeffrey R.7,Cebon Jonathan S.8,Schuchter Lynn Mara9,Long Georgina V.10,Algazi Alain Patrick11,Kudchadkar Ragini Reiney2,Puzanov Igor3,Lawrence Donald P.12,Kefford Richard13,Kline Amy S.14,Del Buono Heather Lynn14,Sun Peng14,McDowell Diane Opatt14,Flaherty Keith12

Affiliation:

1. UC San Francisco, San Francisco, CA

2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

3. Vanderbilt University Medical Center, Nashville, TN

4. The University of Texas MD Anderson Cancer Center, Houston, TX

5. University of Colorado Cancer Center, Aurora, CO

6. The Angeles Clinic and Research Institute, Los Angeles, CA

7. Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

8. Ludwig Institute for Cancer Research, Austin Hospital, Heidelberg, Australia

9. Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

10. Melanoma Institute Australia and The University of Sydney, North Sydney, Australia

11. University of California, San Francisco, San Francisco, CA

12. Massachusetts General Hospital and Dana-Farber Cancer Institute, Boston, MA

13. Crown Princess Mary Cancer Centre, Sydney, Australia

14. GlaxoSmithKline, Collegeville, PA

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3